AI Consensus Investment Thesis
Guardant Health (GH) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$148
-17.7%5-Year
PARTIAL SELL$164
-8.5%Latest flagship insight
Diagnostic Volume Compounding Collides With High Multiple Valuation Compression
High consensus confirms rapid screening and oncology volume compounding alongside laboratory automation gains. Sharp divergence centers on whether persistent commercial customer acquisition costs and multiple compression under restrictive monetary conditions will severely erode common equity returns before cash-flow breakeven arrives.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Michael Burry (Vulture), Machiavelli (Insider), Elon Musk (Visionary), Ray Dalio (Strategist), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Guardant Health at the forecast anchor (2026-09-18): $9,149 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 166.57 | -7.14% | -7.14% | Initial multiple compression dominates as high interest rates penalize unprofitable duration assets, offsetting accelerating commercial screening test volume and healthy therapy selection demand. |
| Q1 2027 | 156.20 | -6.22% | -12.92% | Full-year financial guidance reveals elevated commercial detailing expenditures, prompting institutional investors to moderate near-term cash flow expectations despite strong underlying specimen growth. |
| Q2 2027 | 153.82 | -1.52% | -14.25% | Expanding oncology companion diagnostic indications and rising minimal residual disease testing volume deliver solid gross profit contributions, sparking a tactical operational relief rally. |
| Q3 2027 | 147.61 | -4.04% | -17.71% | Commercial payer policy implementation introduces realized reimbursement dilution, increasing working capital requirements and keeping forward sales multiples under steady pressure. |
| Q4 2027 | 141.57 | -4.09% | -21.08% | Focus turns toward debt maturity management and corporate cash burn, driving moderate multiple de-rating as markets digest screening salesforce investment requirements into year-end. |
| Q1 2028 | 136.93 | -3.28% | -23.67% | Automated laboratory sequencing workflows begin lowering unit processing costs, mitigating margin drag and reassuring investors of progressing operational leverage across centralized facilities. |
| Q2 2028 | 135.16 | -1.29% | -24.65% | Primary care physician adoption expands, but distribution competition and physician detailing expenses temper net margin progression, keeping equity valuation in a consolidation phase. |
| Q3 2028 | 136.97 | +1.34% | -23.64% | Recurring longitudinal monitoring for cancer survivors accelerates, generating predictable high-margin diagnostic streams that stabilize enterprise valuation amid ongoing screening buildouts. |
| Q4 2028 | 137.63 | +0.49% | -23.27% | Improving unit economics and decelerating cash burn offset macro discount rate headwinds, allowing shares to find a firm fundamental floor grounded in diagnostic throughput. |
| Q1 2029 | 140.85 | +2.34% | -21.48% | Fourth-quarter results demonstrate quarterly operating cash burn approaching breakeven, removing solvency overhang and encouraging accumulation by fundamental healthcare growth allocators. |
| Q2 2029 | 144.57 | +2.64% | -19.40% | Initial positive operating cash flow emerges as laboratory automation efficiencies materialize, allowing top-line growth to translate cleanly into corporate margin expansion. |
| Q3 2029 | 144.74 | +0.11% | -19.31% | Routine commercial payer fee renegotiations slightly temper average selling prices, inducing mild consolidation while underlying clinical testing volume maintains healthy momentum. |
| Q4 2029 | 148.25 | +2.43% | -17.35% | Biopharma partnerships and data licensing agreements generate high-margin milestone receipts, diversifying corporate revenue streams and reinforcing enterprise profitability. |
| Q1 2030 | 150.43 | +1.47% | -16.14% | Full-year results confirm sustained operational self-sufficiency, enabling institutional investors to value the business on sustainable cash generation rather than speculative top-line multiples. |
| Q2 2030 | 153.97 | +2.36% | -14.16% | International commercialization and multi-cancer trial milestones expand pipeline optionality, supporting steady equity compounding across established clinical channels. |
| Q3 2030 | 154.10 | +0.08% | -14.09% | Maturing domestic screening growth rates prompt valuation stabilization, as predictable repeat testing cadences replace early launch enthusiasm across primary care networks. |
| Q4 2030 | 157.80 | +2.40% | -12.03% | Expanding operating margins approach mature medtech levels, enabling debt de-leveraging and equity accretion that offset historical convertible share dilution. |
| Q1 2031 | 159.25 | +0.92% | -11.22% | Convertible debt settlements expand the diluted share count, creating mild per-share earnings friction that temporarily dampens quarterly equity appreciation. |
| Q2 2031 | 162.43 | +2.00% | -9.45% | Demonstrated free cash flow generation easily absorbs capital requirements, driving disciplined earnings-driven share appreciation as the core diagnostic moat widens. |
| Q3 2031 | 164.12 | +1.04% | -8.51% | The enterprise achieves terminal valuation equilibrium as an established, profitable precision oncology diagnostic leader trading on normalized cash-flow multiples. |
The base-case economic argument recognizes Guardant as a preeminent clinical engine whose rapid volume adoption in primary-care screening and therapy selection is temporarily decoupled from shareholder value creation. At twenty times sales in a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry, current equity valuation discounts frictionless commercial execution and immediate operational leverage. In reality, customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry across decentralized primary care networks remain elevated, while statutory private-payer median dynamics threaten to dilute blended average selling prices. The strongest counterargument emphasizes that automated sequencing workflows and high-margin recurring therapy selection provide sufficient contribution margin to achieve self-funding status earlier than consensus models anticipate.
Key insights
- Primary care commercialization imposes heavy distribution friction that dilutes gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry before network density yields genuine operational leverage.
- Blended average selling prices face structural compression as private-payer commercial contracts expand relative to initial Medicare statutory benchmarks.
- In-the-money convertible note structures and historical balance-sheet deficits ensure that operating growth leaks into dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry rather than per-share value.
Guardant Health is successfully expanding blood tests for cancer detection, but its high stock price already assumes perfect execution. While more doctors are ordering these tests, marketing them across thousands of clinics is expensive and keeps cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry high. Furthermore, as private insurers negotiate lower prices, revenue per test will decline. Although lower lab costs will eventually help the company turn profitable, multiple contraction will likely limit stock returns.
Key insights
- Selling screening tests to primary care doctors requires heavy marketing spending that delays profitability.
- Private health insurers pay lower rates than Medicare, reducing average revenue per test processed.
- Substantial convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry obligations mean new shares will be issued, diluting common stockholder returns.
Deep Dive
Market consensus views Guardant Health as the anointed winner of blood-based cancer screening, expecting commercial coverage wins and FDA approvals to translate effortlessly into frictionless, software-like profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry. Euphoric commentary anchors on an enormous addressable screening market, assuming twenty-times-sales multiples are justified by volume compounding while dismissing persistent cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and high capital costs.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus views Guardant Health as the anointed winner of blood-based cancer screening, expecting commercial coverage wins and FDA approvals to translate effortlessly into frictionless, software-like profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry. Euphoric commentary anchors on an enormous addressable screening market, assuming twenty-times-sales multiples are justified by volume compounding while dismissing persistent cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and high capital costs.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates the speed at which clinical volume converts into net owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry, leaving shares overvalued. The analytical edge lies in recognizing that primary-care customer acquisition incurs heavy commercial friction, while blended test reimbursement will naturally decline as commercial insurers enforce contracted fee schedules below initial Medicare rates. Operating expansion is real, but multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry will constrain equity returns.
Repricing Catalyst
What could make the market recognize and close that gap? Upcoming earnings releases through 2027 showing widening commercial marketing expenses alongside sequential declines in realized revenue per screening test will close the gap. When market participants observe that volume growth fails to rapidly narrow quarterly cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, sell-side analysts will be forced to compress revenue multiples toward historical medtech diagnostic averages.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- High Erratic
- Cycle position
- Overshoot
Reports agree on high near-term volatility and narrative overshoot, but diverge sharply on cycle duration: bears see imminent valuation collapse, while pragmatists project a multi-year digestion of valuation multiples through revenue growth.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic environment of elevated policy rates and high sovereign benchmark yields is a severe headwind. High borrowing costs penalize long-duration, unprofitable growth companies by increasing the discount ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry on distant cash flows and raising the expense of refinancing convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry obligations.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on the magnitude and duration of multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry versus operational growth. Bullish perspectives argue that accelerating test volumes and automated laboratory efficiencies will rapidly offset multiple contraction, enabling equity appreciation as free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry inflects. Bearish perspectives assert that paying twenty times sales for a business with negative equity and persistent cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry guarantees severe equity destruction once statutory reimbursement resets take effect. This debate will be resolved by observing whether realized commercial selling prices remain resilient as test volumes scale through 2027.
Base-Case Forces
Event Risk ScoreVery High91/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Screening commercial reimbursement cascade | Competitive Positioning | +38% | +55% | FDA approval and commercial coverage inclusion across major benefit managers establish an accessible pathway for colorectal screening. Converting unscreened cohorts drives volume expansion, spreading fixed laboratory overhead across expanding sample counts and lifting recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry. |
| Therapy selection companion diagnostic dominance | Innovation And Product | +26% | +35% | FDA companion diagnostic approvals and minimal residual disease surveillance embed comprehensive genomic profiling directly into standard oncology regimens. Recurring multi-draw testing cadences build high-margin diagnostic revenue streams, insulating baseline cash generation from point-in-time screening cyclicality. |
| Sequencing workflow and assay automation | Operational Efficiency | +20% | +35% | Transitioning high-throughput screening assays to automated sequencing architectures drives down unit processing and reagent costs per sample. This efficiency dividend expands corporate gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry toward seventy percent, turning fixed laboratory overhead into operational leverage. |
| Biopharma data and translational partnerships | Sector And Industry | +15% | +25% | Pharmaceutical sponsors increasingly integrate liquid biopsy platforms into oncology clinical trials for patient stratification. Companion diagnostic co-development milestones and biomarker data monetization generate high-margin cash inflows, partially diversifying revenues away from commercial reimbursement disputes. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry under monetary tightening | Macroeconomic And Macrofinancial | -38% | -8.0% | Trading at an elevated price-to-sales multiple while generating operating losses leaves equity valuation vulnerable to higher discount rates. Sustained restrictive interest rate policy enforces multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward mature diagnostic peer averages, placing a mechanical ceiling on share appreciation. |
| Commercial payer reimbursement dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry | Regulatory | -24% | -30% | Transitioning from statutory initial Medicare payment rates to negotiated commercial private-payer medians mechanically dilutes blended average selling prices. As commercial contract volume expands, lower realized revenue per test compresses operating gross profits relative to optimistic expectations. |
| High primary care commercial detailing burn | Operational Efficiency | -22% | -30% | Detailing decentralized primary care clinics and direct-to-consumer outreach requires continuous marketing and sales expenditures. These distribution costs absorb laboratory gross profits, keeping operating cash flows negative and deferring corporate self-funding status. |
| Convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and capital deficits | Capital Allocation | -18% | -18% | Carrying over one billion dollars in convertible notes alongside accumulated stockholders' equity deficits creates balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry vulnerability. Noteholder conversions expand the common share floatfloatThe number of shares available for public trading in the market.View full glossary entry, diluting future per-share earnings accretion as the core business approaches operational profitability. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Private payer median statutory price collapse | 32% | -45% | A sharp reduction in Medicare reimbursement driven by aggressive commercial private-payer discounting could cut unit revenues by over thirty percent. This statutory tariff reset would erase projected screening profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry, expanding annual cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and forcing emergency dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry financing. |
| Precancerous adenoma competitor leapfrogging | 28% | -45% | A competing diagnostic platform demonstrating materially superior advanced adenoma sensitivity alongside high cancer specificity could capture primary care guidelines. Clinicians would relegate blood tests lacking precancer detection to secondary refusal status, severely impairing long-term volume adoption and stranding commercial infrastructure. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| USPSTF Category A guideline parity | 30% | +55% | The Preventive Services Task Force could unexpectedly grant blood screening Category A or B status during upcoming guideline updates, legally mandating commercial coverage without cost-sharing. Eliminating patient copay barriers would instantly accelerate primary care prescription volumes, pulling forward cash-flow breakeven by multiple years. |
| Pan-cancer screening clinical validation breakthrough | 22% | +65% | Pivotal prospective trial data validating multi-cancer early detection panels could trigger expedited regulatory clearance across solid tumors. Expanding addressable screening markets beyond colorectal cancer would position the company as a multi-cancer utility, attracting premium biopharma partnerships and expanding institutional valuation multiples. |
Company Financial Analysis
Guardant Health Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Top-line revenue demonstrates explosive momentum, driven by rapid adoption of Shield colorectal screening and double-digit volume expansion in therapy selection testing. Recent quarters show revenue growing over forty percent year-over-year, confirming robust physician demand for non-invasive liquid biopsy options. However, this revenue expansion conceals persistent operational unprofitability. Heavy selling, general, and administrative expenditures required to detail decentralized primary care physicians continue to devour gross profits. With annual net losses exceeding four hundred million dollars and negative free cash flow, top-line growth remains subsidized by balance sheet liquidity rather than self-funding operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 982M | USD -416.3M | USD -233.1M |
| 2024 | USD 739M | USD -436.4M | USD -274.9M |
| 2023 | USD 563.9M | USD -479.4M | USD -345.5M |
| 2022 | USD 449.5M | USD -654.6M | USD -386.9M |
| 2021 | USD 373.7M | USD -405.7M | USD -284.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gross profit margins have expanded toward sixty-seven percent, demonstrating authentic manufacturing efficiency as automated sequencing platforms and chemistry optimizations reduce unit processing costs per sample. The core laboratory engine exhibits favorable contribution economics on each test processed. Conversely, operating margins remain deeply submerged in negative territory due to massive commercialization overhead. Selling blood-based screening tests across tens of thousands of family doctors requires an extensive commercial salesforce and marketing expenditure. Sustainable operating profitability depends on physician ordering habits becoming self-sustaining without requiring proportional increases in commercial spending.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -437.2M | -44.5% | -42.4% |
| 2024 | USD -443.6M | -60.0% | -59.0% |
| 2023 | USD -564.7M | -100.1% | -85.0% |
| 2022 | USD -544.4M | -121.1% | -145.6% |
| 2021 | USD -411M | -110.0% | -108.6% |
Balance sheet and leverage
AI Review
The balance sheet displays an acute contrast between substantial short-term liquidity and long-term structural leverage. Over one billion dollars in cash and marketable securities provides adequate operational runway for the immediate future, buffering ongoing commercial investments. However, cumulative historical losses have produced a deficit in stockholders' equity, leaving the enterprise with negative book value. Furthermore, gross liabilities include over one billion dollars in convertible notes maturing between 2027 and 2033. Because the stock trades above key conversion strikes, noteholders will likely convert into common shares, eliminating default risk but imposing notable equity dilution.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 1.7B | USD 1.2B | USD 1.3B net debt | 4.84x |
| 2024 | USD 1.3B | USD 840M | USD 810.5M net debt | 4.68x |
| 2023 | USD 1.4B | USD 1.2B | USD 220.2M net debt | 6.54x |
| 2022 | USD 1.4B | USD 1B | USD 1.2B net debt | 6.17x |
| 2021 | USD 1.4B | USD 932.7M | USD 881.5M net debt | 5.72x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Guardant operates an asset-light physical model, keeping direct property and equipment expenditures modest at roughly five percent of revenue. Laboratory facility expansions in recent years provide sufficient physical footprint to process rising specimen throughput without requiring massive industrial machinery buildouts. Instead, capital allocation is concentrated in operational research and development and clinical trial execution. Management commits hundreds of millions annually to optimize sequencing chemistry, automate assay workflows, and validate multi-cancer detection pipelines. This intangible investment preserves technological leadership but defers distributable cash generation into future years.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 48.3M | USD 364.2M |
| 2024 | USD 35.1M | USD 347.8M |
| 2023 | USD 20.5M | USD 367.2M |
| 2022 | USD 77.5M | USD 373.8M |
| 2021 | USD 75M | USD 263.2M |
Quarterly Forecast Scenarios
Guardant Health Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $152.47 | $167.21 | $184.76 | $750.26 | |
| $134.18 | $156.27 | $186.61 | $736.44 | |
| $136.60 | $151.84 | $177.28 | $743.40 | |
| $124.30 | $145.07 | $166.88 | $755.15 | |
| $114.43 | $138.77 | $175.22 | $776.22 | |
| $102.62 | $133.31 | $164.71 | $787.13 | |
| $94.60 | $131.27 | $174.59 | $802.83 | |
| $93.57 | $132.76 | $181.57 | $812.05 | |
| $91.49 | $133.79 | $187.02 | $839.18 | |
| $83.26 | $136.42 | $192.47 | $850.50 | |
| $79.10 | $139.77 | $200.30 | $872.39 | |
| $81.47 | $139.96 | $198.17 | $885.51 | |
| $76.58 | $143.10 | $204.11 | $909.56 | |
| $72.75 | $145.57 | $214.32 | $916.13 | |
| $74.21 | $148.84 | $220.75 | $936.51 | |
| $71.24 | $148.54 | $222.70 | $947.34 | |
| $71.95 | $152.11 | $231.61 | $969.59 | |
| $69.07 | $153.92 | $236.24 | $979.99 | |
| $71.15 | $156.95 | $243.33 | $999.60 | |
| $69.01 | $158.75 | $248.20 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The consensus centers on an undeniable divergence between clinical volume adoption and shareholder economics. A common pattern across all fourteen analyses is the explosive adoption of blood screening and therapy selection, offset by high commercialization overhead and multiple compression in a tight monetary regime. However, significant correlated assumptions exist regarding the timing of cash-flow breakeven and the severity of terminal multiple contraction. Downweighted opinions assume catastrophic liquidation or extreme multiple collapse below four times sales, which fails to account for verified commercial payer coverage wins and companion diagnostic pricing power. Conversely, top weights are assigned to Polymath models that incorporate forensic balance sheet analysis, verifiable convertible debt dilution mechanics, and realistic average selling price adjustments without succumbing to one-sided extremes.
Universal Investor AI
The Polymath
Opus 5Outstanding factual verification of Q2 2026 results, detailed convertible debt strike structures, and commercial ASP dilution mechanics. Balances explosive screening volume growth against near-term cash burn realities.
Universal Investor AI
The Polymath
GPT-6 AstraDemonstrates rigorous balance sheet cross-checks including the convertible debt maturity profile and realistic dilution mechanics. Grounded heavily in verified SEC filings and FDA companion approvals, presenting a measured multiple compression path.
Universal Investor AI
The Polymath
Gemini 3.8 FlashDetailed synthesis of commercial payer cascade dynamics and NovaSeq automation economies. Effectively balances initial reimbursement dilution against compounding primary care test adoption.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashCaptures customer acquisition frictions across decentralized primary care networks and macroeconomic discount rate pressures. However, assumes severe multiple contraction despite strong commercial volume uptake across major payer networks.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashAccurately highlights the macroeconomic friction of sustained interest rates and duration repricing, but overstates terminal multi-year revenue multiple collapse relative to expanding liquid biopsy operating leverage.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashPresents strong insight into statutory reimbursement dynamics and companion diagnostic moats, but incorporates overly aggressive multiple compression assumptions given durable therapy selection testing volume growth.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashProvides valid analysis of primary care commercial detailing overhead and negative book equity, but downweights laboratory automation efficiencies and prospective biopharma data monetization opportunities.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSound breakdown of assay automation and companion diagnostic pipelines, though overemphasizes multiple contraction relative to top-line volume elasticity across commercial screening cohorts.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashStrong forensic accounting focus on cash burn and working capital requirements, though terminal multiples appear overly compressed given the potential for operating leverage post-2028.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashInsightful political and regulatory analysis surrounding statutory PAMA reimbursement timelines, balanced against realistic commercial friction in decentralized primary care physician detailing.
Elon Musk AI
The Visionary
Gemini 3.8 FlashCorrectly pinpoints biological limitations regarding precancerous adenoma sensitivity, but projects excessive operational deterioration that understates clinical switching barriers in advanced oncology.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAccurately details convertible bond dilution mechanics, yet discounts ongoing laboratory cost-per-test deflation and the durability of recurring therapy selection testing volumes.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashUnderweights structural clinical moats in therapy selection and recurring minimal residual disease monitoring, resulting in an excessively punitive downside projection that neglects operational scale efficiencies.
Michael Burry AI
The Vulture
Gemini 3.8 FlashHighlights real insider selling and potential PAMA statutory reset risks, but adopts an overly extreme liquidation scenario that discounts verified commercial payer coverage expansion.
Research Provenance
References & Context
This Guardant Health consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 85 deduplicated sources retained for this batch.
- 01Premarket Approval (PMA)accessdata.fda.gov
- 02Premarket Approval (PMA)accessdata.fda.gov
- 03FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDAfda.gov
- 04MCGP May 23, 2024 FDA Executive Summaryfda.gov
- 05Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 06gh-20251231sec.gov
- 07gh-20260630sec.gov
- 08Guardant Health, Inc. - Form 8-K - FY2026sec.gov
- 09Guardant Health, Inc. - Form 8-K - FY2026sec.gov
- 10www.businesswire.combusinesswire.com
- 11Guardant Health at Morgan Stanley conference: shield scales, cdx gains By Investing.comca.investing.com
- 12Colorectal Cancer | American Cancer Societycancer.org
- 13Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathwayexactsciences.com
- 14Guardant Health (GH) Just Gave Investors Something To Think Aboutfinance.yahoo.com
- 15Guardant Health Inc (GH) (Q2 2026) Earnings Call Highlights: Revenue Surges 44% on FDA Approval ...finance.yahoo.com
And 70 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2016-12-31–2025-12-31, 10 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.